Objective: Cartilage oligomeric matrix protein (COMP) is a component of articular cartilage whose serum levels show a strong correlation with radiographic osteoarthritis (OA) status. It has recently been found, however, that COMP is also produced in synovium. To assess the hypothesis that synovitis affects serum COMP levels in patients with knee OA, we collected sera for COMP simultaneous with a clinical examination for synovitis.
Introduction
Cartilage oligomeric matrix protein (COMP) is a member of the thrombospondin family of extracellular calcium-binding proteins that was initially isolated from cartilage 1 . COMP is a non-collagenous glycoprotein of high molecular weight (>500 kDa), composed of five identical subunits 2 . Primary sequences of rat, mouse, and human COMP have been determined so far 2, 3 . The carboxy-terminal globular domain of native COMP binds to collagens I and II 4 . A five-stranded coiled-coil domain, formed when subunits assemble their amino-terminal ends into an oligomer 5 , may have a storage and delivery function for hydrophobic cell signaling molecules such as vitamin D 6 . The significance of COMP for normal development and function of cartilage has been underscored by the discovery that mutations of the COMP gene result in pseudoachondroplasia and some forms of multiple epiphyseal dysplasia 7 . Osteoarthritis (OA) is a common disease causing pain and disability in a significant proportion of the adult population 8 . It is characterized by the progressive destruction of articular cartilage and concomitant changes in subchondral bone 9 . A diagnosis of knee OA, traditionally based upon weight-bearing radiographs and pain, is usually made by the time tissue destruction is already advanced. Therefore, much attention has been focused on developing assays for cartilage derived macromolecules or their fragments whose release into the circulation from the joint may reflect disturbances in joint tissue turnover. Although many unresolved questions remain 10 , such 'markers' may provide insight into the early stages of the disease 11 as well as facilitating diagnosis, prognosis and disease severity evaluation 12 . COMP has been suggested as a promising candidate molecular marker of OA 13 , especially because it has been shown to be relatively specific to joint tissues.
Most previously published studies reporting serum COMP levels in OA have concentrated on its use as a potential prognostic marker; in all these studies COMP has been measured by enzyme linked immunosorbent assay (ELISA) with polyclonal antibodies. Two of these studies have demonstrated an association of increasing serum COMP levels with progression of OA monitored radiographically. In the study by Sharif et al. 14 , serum COMP increased significantly in patients with clinical knee OA who showed decreased joint space or required knee surgery during a five-year follow-up period. Petersson et al. 15 determined serum concentrations of COMP over a 3-year period in individuals with chronic knee pain (with or without radiographic evidence of knee joint OA at study entry) and found that COMP levels increased significantly only in the individuals with radiographic OA at follow-up, while remaining unchanged in the individuals with normal radiographs at follow-up. Conrozier et al. 16 showed that baseline serum COMP correlated with mean joint space narrowing over 1 year in symptomatic hip OA patients. No correlation has been found in another study comparing baseline serum COMP levels to disease progression defined arthroscopically over a 1-year period 17 . In addition, serum concentrations of COMP, measured in a group of individuals with chronic knee pain, has correlated positively with the extent of bone scan abnormalities 18 . Taken together, the results of studies performed so far are promising with regard to COMP as an OA biomarker; their interpretation however, has been complicated by recent discoveries that, besides cartilage, COMP is produced by practically all tissues within a joint, namely tendon 19 , ligament and meniscus 20 , and synovium [21] [22] [23] [24] [25] . This finding has led some authors to speculate that synovitis may affect serum COMP level by influencing synovial tissue synthesis and release of COMP into the circulation 24, 25 . We have developed a panel of monoclonal antibodies (mAbs) to human COMP and we used one of them, 17-C10, to develop a competitive indirect inhibition ELISA for COMP 26 . The mAb 17-C10 recognizes a conformational epitope in a domain of EGF-like repeats 27 that is located near the center of a COMP subunit, and as such it should be unaffected by partial, N-or C-terminal, cleavage of the antigen. Like polyclonal antibodies used by other authors previously, the 17-C10 mAb does not appear to distinguish between COMP produced by chondrocytes and COMP produced by synovial fibroblasts 28 . Our previous studies on sera have demonstrated that mAb 17-C10 is capable of distinguishing groups of OA-affected and unaffected (no radiographic hip or knee OA) subjects, and also subgroups of OA patients sorted by severity of OA and number of knee and hip joints involved 29 . The goal of this study was to assess the influence of synovitis, a common and important clinical sign often manifested with OA, on serum COMP levels.
Patients and methods

PATIENTS
This study was approved by the local research ethics committee. Patients seen consecutively over a 6-month period in the outpatient clinic of the Institute of Rheumatology, Prague, Czech Republic, with knee pain and who fulfilled the American College of Rheumatology criteria for knee OA 30 were recruited into the study. All eligible patients (N=196) chose to participate. Blood was collected for serological studies, and standing anteroposterior radiographs of both knees were performed.
Radiographs of tibiofemoral joints were classified according to the grading system of Kellgren and Lawrence (K-L) 31 . A single radiologist (JG) scoring the radiographs was blinded to the results of the clinical exam. Patients were examined by a single rheumatologist blinded to the radiographic results, who clinically assessed three signs of knee joint inflammation, tenderness (T), non-bony swelling (S), and warmth (W), and graded each sign on a scale of 0-3 according to the method of Thompson 32 resulting in total scores ranging from 0 to 9. Tenderness was assessed by palpation along the joint-line (capsular/joint-line tenderness, which suggested capsular/intracapsular origin of pain). Swelling was assessed by clinical tests used for detection of synovial fluid presence (palpation, bulge sign). Warmth was assessed by the investigator's palm after patients accommodated to the local room temperature. Synovitis of the knee was defined as the presence of joint tenderness of at least grade 1 plus swelling and/or warmth of at least grade 1 for the same knee. The reproducibility of the determination of all three clinical signs of inflammation and of the presence of clinical synovitis overall was estimated by repeating the examination of 15 patients (30 knees) by the study rheumatologist on two consecutive days. For particular signs of knee joint inflammation, i.e., T, S, and W, the reproducibility was 83%, 90%, and 86.7%, respectively; the intra-observer reproducibility for presence of clinically diagnosed synovitis was 80%. Patients were interviewed to obtain a global patient assessment of disease severity referred to here as the ISK score or 'Index of Severity for Knee Osteoarthrosis' 33 where higher scores are indicative of more severe disease. The clinical examination and blood collection were performed concurrently on fasting patients instructed to refrain from the use of their arthritis medications on the morning of the evaluation.
IMMUNOASSAYS
Sera were obtained from blood samples collected in sterile tubes without additives, and stored at −80°C. C-reactive protein (CRP) levels were measured simultaneously by two methods: (a) by immunoturbidimetric assay kit commercially available from Boehringer Mannheim Systems and (b) by sensitive sandwich ELISA supplied as a kit (UBI MAGIWELL CRP QUANTITATIVE AD-401) by UBI, Mountain View, CA, U.S.A. CRP levels determined by both methods were correlated (P<0.0001) when compared using the Spearman correlation coefficient (r) (not shown).
COMP was analysed by inhibition ELISA essentially as previously described 26 , with several minor modifications. Briefly, plate coating was performed with coating buffer (20 mM carbonate/bicarbonate, pH 9.2, 0.002% sodium azide) containing human articular cartilage COMP at 5 g/ ml. Nunc-Immuno (MaxiSorp) plates (Nunc, Denmark) were coated with 50 l/well, covered with plate sealing tape and kept at 4°C until used. COMP standard, purified as previously described 26 from human articular cartilage, was initially diluted to 1 g/ml. An initial serum dilution of 1:2 was used. Standards as well as samples were further diluted in PBS-0.05% Tween 20, pH 7.3 (TPBS) in a Nunc Microwell (low-binding) plate (Nunc, Denmark). Anti-(human)COMP Mab 17-C10 26 was diluted 1:40,000 in TPBS/1% bovine serum albumin (TPBS/BSA). Primary antibody (70 l) was added to 70 l of the COMP standard or patient sera. The inhibition mixtures were incubated at 4°C overnight. A 100 l aliquot of these inhibition mixtures was transferred into washed coated wells of the NuncImmuno plate and incubated for 60 min at 4°C. The plates were then washed and received 100 l/well of a solution of horse radish peroxidase-conjugated rabbit anti-mouse immunoglobulin antibody, absorbed with human immunoglobulins (Dako A/S, Denmark) diluted 1:1000 with TPBS/BSA. After incubating for 60 min at room temperature, unbound antibody was removed by washing and 100 l of substrate (o-phenylenediamine plus H 2 O 2 ) was placed into the wells for 30-60 min at room temperature. The production of chromophore was stopped by the addition of 50 l of 2 M H 2 SO 4 . The plates were read at a wavelength of 490 nm. Results are expressed as equivalents of the standard human antigenic COMP ( g/ml). Each plate contained four identical samples of 'control' sera which were kept aliquoted and frozen at −70°C. Each day a fresh aliquot of these control samples was thawed and used on every plate to calculate intra-and interassay variance of the assay 34 . We found intra-and interassay variance of the assay to be less than 4% and less than 5%, respectively. Analyses were performed without knowledge of the clinical data.
STATISTICAL METHODS
Geometric means and their 95% confidence intervals (95% CI) were calculated. Differences between ln-transformed serum COMP levels [ln(COMP)] in groups of patients sorted according to K-L grade and synovitis were assessed by two-way ANOVA. Natural logarithm transformation of serum COMP levels was done in order to satisfy the assumptions of a Gaussian distribution of the data underlying the use of ANOVA methods. To describe dependency of ln(COMP) on age and gender and to test for an effect of other factors on ln(COMP) we used multiple linear regression. From each of the models, regression coefficients and their 95% confidence intervals were calculated. Linear regression model was also used for adjusting the geometric mean to the mean age. Scores of three clinical signs of knee joint inflammation (T+S+W) were compared to CRP levels using the Spearman correlation coefficient (r). A P-value of <0.05 was considered significant.
Results
Clinical and radiographic data were obtained at the time of sera collection on 196 patients. The patients were predominantly female with bilateral knee OA ( Table I) . The most severely diseased knee was used for purposes of grading, when bilateral knee OA of different grades was present. This occurred in 51 of the 156 bilateral knee OA cases and in 39 of the bilateral knee OA cases in the female subgroup. Synovitis at the time of sera collection was present in 68% of patients and was slightly more prevalent in the more severely affected OA knees (synovitis in 74% of K-L grade >2) compared with the less severely affected OA knees (synovitis in 65% of K-L grade ≤2). Although a total of 51 cases of bilateral knee OA demonstrated more severe OA in one knee compared with the other, the majority of clinically detected synovitis occurred in the more severely affected knee (44 of 51 cases or 86%). Table II summarizes unadjusted serum COMP levels by OA severity and presence of synovitis. COMP levels were higher in the group with K-L grade >2 knee OA (1.197 g/ ml) compared with the group with less severe K-L grade ≤2 OA (1.029 g/ml) (P=0.002 by two-way ANOVA using ln transformed COMP). COMP levels were also higher in the group with synovitis (1.127 g/ml) compared with the group lacking synovitis (1.007 g/ml) (P=0.038).
The effect of age, gender, and interaction of age and gender on ln(COMP) was tested by multiple regression. The multiple correlation coefficient was 0.482 (P<0.001). The effect of age on ln(COMP), when tested by means of linear regression, was different for males (correlation coefficient 0.121, NS) and females (correlation coefficient 0.524, P<0.001) (Fig. 1) . Non-parallelism of both gender groups was highly significant (P<0.001). Thus, age and gender have to be considered confounding variables with regard to serum COMP levels.
Since the proportion of females recruited into the study was much higher than that of males, and since the characteristics of the subgroup of female patients were similar to the characteristics of the group as a whole (Table I) , we 30 . Table IV . Besides age, serum COMP was influenced by synovitis and by an interaction of synovitis and K-L grade. K-L grade alone however was not significantly correlated to ln(COMP) levels whereas synovitis alone was significant, showing the strongest effect of all the variables examined with a regression coefficient of 0.1587 (P<0.01). There was no significant effect of CRP level, ISK or disease duration on ln(COMP). The effect of three clinical signs of synovitis (T, S, and W) on ln(COMP), was tested for the subgroup of female patients using two independent models of linear regression, including age as a confounding variable. For each patient, the indices of synovitis were summed across both knees to give a total grade for T, S, and W. The simple regression model was used for sum of grades of all three signs (T+S+W); the multiple regression model was used to test for the effect of three signs separately (Table V) . The linear regression model was significant for: (i) sum of total grades of all three signs (T+S+W); (ii) total grade of tenderness (T); (iii) total grade of warmth (W). The effect of the total grade of swelling (S) was not significant. The sum of grades of all three clinical signs of synovitis (T+S+W) did not correlate significantly with CRP level (P=0.079), when compared using the Spearman correlation coefficient.
Discussion
We have detected significant differences in unadjusted serum COMP levels, measured by ELISA with mAb 17-C10, between groups of patients with knee OA sorted according to radiographic grade (K-L grade ≤2 vs K-L grade >2) or according to the presence of clinically diagnosed synovitis of the knee. However, we have identified age as a confounding variable. After adjusting for age in the subgroup of female patients, only the effect of synovitis on COMP level remained statistically significant. Thus, our study demonstrates a correlation of clinically evident synovitis with serum COMP. Although the differences reported are statistically significant, they are small in terms of actual numerical difference. There is overlap between individual groups differentiated by synovitis thus serum COMP cannot be used as a discriminating test in individuals.
We used two assays to measure blood CRP level. We were concerned that the turbidimetric assay might not be sensitive enough to detect small elevations in CRP level associated with low-grade inflammation accompanying OA and detected by high-sensitivity immunoassays as was described recently 35, 36 . Thus we also measured CRP levels by a very sensitive sandwich ELISA assay. Although blood CRP levels determined by the two different methods correlated highly, neither of them correlated to blood COMP levels or to clinical indicators of knee inflammation. We suggest that serum COMP probably reflects local, OA-associated inflammation localized to a joint, while CRP reflects a systemic inflammatory response, like general infection.
Using a larger sample size and the same mAb to COMP, we have previously observed higher serum COMP levels in individuals with knee OA of K-L grade ≤2 compared to a control population without knee or hip OA 29 . However, in the present study, the difference in serum COMP levels between two groups with knee OA (mild and severe) was not large enough to be statistically significant although the same trend was apparent, with higher mean serum COMP in the more severely affected group. Both studies have shown that serum COMP level increases with age, but this effect is more pronounced in females than in males. The difference between female and male subjects may relate to post-menopausally increased bone metabolism characterized by up-regulated osteoclastic and osteoblastic activity, since, according to a recent finding 37 , COMP is also expressed by osteoblasts.
Although the study populations in these two studies (this and Clark et al. 29 ) were very different, one a rural population in North Carolina, the other an urban population in middle Europe (both Caucasian), the 17-C10 ELISA measured very similar levels of serum COMP. This agreement was achieved by using the same mAb to COMP in addition to the same standard of human cartilage COMP in both studies. Although an internationally recognized COMP standard is not available, the advent of mAbs for COMP may aid in the standardization of COMP assays whose feasibility is demonstrated here. Compared to studies that measured COMP by ELISA with polyclonal antibodies [13] [14] [15] [16] [17] [18] , we report lower (by approximately 10-fold) levels of serum COMP. There are several possible explanations of this difference; the 17-C10 mAb may detect a narrower range of serum COMP fragments than is detected by polyclonal antibodies, and the purity of our standard may be greater, yielding overall lower COMP values.
Synovium is known to produce COMP [21] [22] [23] [24] [25] and in theory may contribute measurable levels of COMP to the serum. We have detected measurable amounts of COMP in hypertrophic synovium collected at the time of knee surgery from three OA patients 28 . The concentration of COMP in these synovial specimens, determined by ELISA with mAb 17-C10, ranged from 4 to 64 g/g wet weight of tissue. Neidhart et al. 38 detected COMP at concentrations of Best-fit regression lines were calculated independently for female (--) and male (---) patients using linear regression model.
3.40 mg/g and 2.17 mg/g wet weight of human tibial and femoral cartilage, respectively. It can be estimated from these data that the concentration of COMP (per wet weight of tissue) in synovium is about 100 times lower then the concentration in articular cartilage. Supporting this contention, Saxne and Mansson report a similar estimation cited as an unpublished observation 15 . There is no available information at present on the turnover rate of COMP in synovial tissue and in cartilage. These turnover rates may vary by tissue type and by pathological condition. Dodge et al. 24 have reported that cultured human synovial cells produce more COMP (per g DNA) than cultured articular chondrocytes maintained under conditions which promote retention of a cartilage-specific phenotype. DiCesare et al. 25 have found that COMP mRNA levels are three-fold higher in rheumatoid synovium compared to osteoarthritic synovium; the authors concluded from this comparison that inflammatory synovium should be considered a potential source of serum COMP. It has also been shown that a pro-inflammatory cytokine, TGF-, can induce COMP mRNA and protein in synovial fibroblasts 23 . The clinical estimation of inflammation (synovitis) still remains an unresolved problem. Some objective methods (thermocameras, isotopes) have failed, while other modern objective methods (MRI, ultrasound) are not validated for clinical studies yet. Both synovial biopsy and arthroscopy are invasive and their routine use in studies like this are difficult to justify for ethical reasons. Therefore, the recommended tools for clinical detection of synovitis are various joint indices (tender joint count, swollen joint count). We decided to use standard measures of tenderness, swelling, and warmth, performed by a single rheumatologist, to make a clinical determination of synovitis. The reproducibility of clinically determined synovitis in this study was 80%, thus validating the clinical relevance of our serum COMP findings. The association of higher synovitis scores with higher COMP levels might strengthen the evidence of an association of COMP levels with synovitis. However, the associations of the three clinical signs of synovitis with serum COMP levels were not the same. The association with tenderness was the most pronounced while the association with swelling was not significant (Table V) . We concluded that we could not divide patients further into subgroups based upon various levels of the total score for further statistical analysis in a sample of this size.
Episodic inflammation of affected joints is frequent in OA patients and synovitis is common in patients with advanced OA. Synovitis, defined as mononuclear cell infiltration on synovial tissue biopsy, was found in 50% of patients with early knee OA of K-L grade <3 by Myers et al. 39 , while only 38% of all their patients (i.e., 76% of patients with histologically diagnosed synovitis) would have been simultaneously diagnosed clinically by our criteria (pain and effusion and/or warmth), indicating that we have probably missed some cases of inflammation, presenting with less striking clinical symptoms.
Our results suggest that inflamed synovium may either (1) produce COMP in amounts significant enough to be detected in serum by immunoassay with mAb 17-C10 or (2) accelerate cartilage loss of antigenic fragments of COMP, or (3) affect joint clearance of cartilage-derived COMP. All these mechanisms may operate simultaneously and all of them may be partially responsible for the serum COMP level increase. Our results do not necessarily suggest extra-cartilage origin of blood COMP, as it has been shown 
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V. Vilím et al.: Synovitis affects serum COMP levels that even mild synovitis may significantly increase the clearance of a protein from the synovial fluid 40, 41 . On the other hand, COMP produced in synovium may enter the bloodstream directly, and thus may influence serum level more than COMP produced in cartilage, that has to enter the bloodstream via the synovial fluid and may therefore be subject to greater lymphatic uptake. Thus, although the actual mechanism causing the observed effect is unclear, synovitis should be considered a factor that affects serum COMP levels.
In summary, in this study we have identified another factor, besides age and OA severity, that influences the level of serum COMP in patients with knee OA, namely synovitis of the knee. This finding invites consideration of the role that synovitis may play in OA progression in light of studies showing that higher levels of serum COMP indicate patients with faster progressing OA. These results underscore the importance of assessing for synovitis by clinical joint examination in future studies of OA and COMP. , the simple regression model (T+S+W) used for the sum of total grades of all three signs of synovitis, and the multiple regression model (T, S, W) used to test for the effect of three signs of synovitis separately. Standard errors of regression models T+S+W and T, S, W equal to 0.269 and 0.267, respectively; correlation coefficient r (T+S+W) equals to 0.567; multiple correlation coefficient r (T, S, W) equals to 0.586. b=Regression coefficient. NS Not significant; *P<0.05; **P<0.01.
